Glucocorticoid-induced osteoporosis: What is new?;Osteoporosis inducida por glucocorticoides: ¿Qué hay de nuevo?

Reumatologia Clinica

Volumn 3, Issue EXTRA.1, 2007, Pages 3-8

  Aguado Acín, María Pilar ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYANDROSTENEDIONE DEHYDROGENASE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; FIBROBLAST GROWTH FACTOR 2; GLUCOCORTICOID; INTERLEUKIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D; VITAMIN D DERIVATIVE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RESPIRATORY TRACT DISEASE; REVIEW; VERTEBRA FRACTURE;

EID: 44949174915     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96:115-23.
2. Angeli A, Guglielmi G, Dovio A, Capelli G, De Feo D, Giannini S, et al. High prevalence of asymtomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study. Bone. 2006;39:253-9.
3. Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporosis Int. 2005;16:2168-74.
4. Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence. J Clin Endocrinol Metab. 2002;87:4033-41.
5. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 1999;14:1061-6.
6. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab. 2006;17:144-9.
7. Manolagas SC. Corticoteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res. 2000;15:1001-5.
8. Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone. 2004;34:593-8.
9. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews 1999. Issue 1. Art. No. CD001347. DOI: 10.1002/14651858. CD001347.
10. Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int. 2002;13:777-87.
11. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
12. ACR ad hoc Committee on glucocorticoid-induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 update. Arthritis Rheum. 2001;44:1496-503.
13. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Melton III LJ, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-9.
14. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology. 2000;39:1383-9.
15. Gluck OS, Murphy WA, Hahn TJ, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy. Arthritis Rheum. 1981;24:892-8.
16. Van Staa TP, Leufkens HGM, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001;16:581-8.
17. Hubbard RB, Smith CJP, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture. A population-based case-control study. Am J Respir Crit Care Med. 2001;164:1392-7.
18. Lau E, Mandani M, Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am J Med. 2003;114:142-5.
19. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224-9.
20. Kumagal S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, et al. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol. 2005;32:863-9.
21. Van Staa TP, Geusens P, Pols HAP, De Laet C, Leufkens HGM, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. Q J Med. 2005;98:191-8.
22. Bone and Tooth Society of Great Britain, Royal College of Physicians, and National Osteoporosis Society. Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis. London: Royal College of Physicians; 2003.
23. Geusens PP, De Nijs RNJ, Lems WF, Laan RFJM, Struijs A, van Staa TP, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004;63:324-5.
24. Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis Int. 2006;17:8-19.
25. Gourlay M, Franceschini N, Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol. 2006. doi:10.1007/s10067-006-0315-1.
26. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis. 2005;64:176-8.
27. Adachi JD, Papaioannou A. In whom and how to prevent glucocorticoid- induced osteoporosis. Best Practice Res Clin Rheumatol. 2005;19:1039-64.
28. Buckley M, Hillner BE. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol. 2003;30:132-8.
29. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane database of Systematic Reviews 1998, Issue 2. Art. No.: CD000952. DOI: 10.1002/14651858. CD000952.
30. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillesdorf S, Sebaldt RJ, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol. 1996;23:995-1000.
31. Sambrook PN, Schacht E. D-hormones alfacalcidol and calcitriol for prevention and treatment of glucocorticoid/inflammation-induced osteoporosis. J Rheumatol. 2005;32 Suppl 76:1-3.
32. Orimo H, Schacht E. The D-hormone analog alfacalcidol: the pioneer beyond the horizon of osteoporosis treatment. J Rheumatol. 2005;32 Suppl 76:4-10.
33. 3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporosis Int. 2004;15:589-602.
34. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al. Stimulation of osteoprotegerin ligand and inhibition osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140:4382-9.
35. Kobayashi A, Hirano F, Makino I. The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Scand J Rheumatol. 2005;34:480-4.
36. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Inttermitent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337:382-7.
37. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med. 1998;339:292-9.
38. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-18.
39. Boutsen Y, Jamart J, Esselincks W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res. 2001;16:104-12.
40. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-years effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-11.
41. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res. 2000;15:1006-13.
42. Cauza E, Etemad M, Winkler F, Hanusch-Enserer H, Partsch G, Noske H, et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther. 2004;29:431-6.
43. Ringe JD, Dorst A, Faber H, Ibach K, Sorensen F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporosis Int. 2003;14:801-7.
44. Nijs RNJ, Jacobs JWG, Lems WF, Laan RFJ, Algra A, Huisman AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355:675-84.
45. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994;37:1499-505.
46. Reid IR, Wattie DJ, Evans MC, Stapelton JP. Testosterone therapy in glucocorticoidreated men. Arch Intern Med. 1996;156:1173-7.
47. Lane NE, Sánchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest. 1998;102:1627-33.
48. Lane NE, Sánchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res. 2000;15:944-51.
49. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-31.